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BACKGROUND: Hypertension (HTN) is a common toxicity of anti-VEGF (vascular endothelial growth factor) antibody treatment.
It may be a marker of VEGF signalling pathway inhibition and therefore represent a cancer biomarker in metastatic colorectal cancer
(mCRC) patients treated with chemotherapy and bevacizumab.
METHODS: A total of 101 consecutive patients with mCRC were treated with standard chemotherapy combined with bevacizumab
at dose of 2.5mgkg
 1 per week in a single centre. The median follow-up time of the patients alive was 64 months. Blood pressure
was measured before each bevacizumab infusion, and HTN was graded according to common toxicity criteria for adverse events
version 3.0.
RESULTS: Overall, 57 patients (56%) developed Xgrade 1 HTN (median blood pressure 168/97mmHg), whereas 44 (44%) remained
normotensive when treated with bevacizumab-containing chemotherapy regimen. Overall response rate was higher among patients
with HTN (30 vs 20%; P¼0.025). Hypertension was associated with improved progression-free survival (10.5 vs 5.3 months;
P¼0.008) and overall survival (25.8 vs 11.7 months; Po0.001), and development of HTN within 3 months had an independent,
prognostic influence in a multivariate landmark survival analysis together with other known mCRC prognostic factors (P¼0.007).
There was no association between HTN and development of thromboembolic complications.
CONCLUSION: Hypertension may predict outcome of bevacizumab-containing chemotherapy in mCRC. These data require
confirmation in prospective studies including pharmacodynamic and pharmacokinetic analyses.
British Journal of Cancer (2011) 104, 599–604. doi:10.1038/bjc.2011.2 www.bjcancer.com
Published online 8 February 2011
& 2011 Cancer Research UK
Keywords: bevacizumab; hypertension; predictive factor
                                                       
Bevacizumab is an anti-VEGF (vascular endothelial growth factor)
monoclonal antibody shown to be effective in the treatment
of metastatic colorectal cancer (mCRC). According to several
randomised studies bevacizumab prolongs both progression-free
and overall survival (OS) (Ranpura et al, 2010). In all studies,
hypertension (HTN) has been recognised as a common adverse
event associated with bevacizumab treatment (Ranpura et al,
2010).
Although not all patients diagnosed with mCRC do benefit from
anti-VEGF antibody treatment, there are currently no biomarkers
available for the prediction of the efficacy of antiangiogenic
therapies. Hypothetically, HTN might be such a predictor, as VEGF
signalling pathway inhibition removes endothelial cell survival
signal leading to apoptosis and capillary rarefaction. It also
reduces the amount of endothelial cell-derived nitric oxide,
causing vascular smooth muscle constriction, increased vascular
resistance, and elevated blood pressure (Dvorak, 2002). Recently,
bevacizumab-associated HTN has been suggested to predict
treatment efficacy in metastatic renal cell cancer patients treated
with single-agent bevacizumab or sunitinib (Bono et al, 2009;
Rini et al, 2010b). In this study, we investigated whether treatment-
related HTN is associated with outcome and safety in 101
consecutive mCRC patients treated with bevacizumab-containing
chemotherapy in a single centre.
PATIENTS AND METHODS
Patients and treatment
Bevacizumab has been used as a standard treatment in mCRC at
the Department of Oncology, Helsinki University Hospital
(HUCH), since April 2004. During the inclusion period (April
2004–December 2005), 114 consecutive patients treated with
chemotherapy and bevacizumab were recognised. No patients
were excluded due to baseline HTN. Hypertension and response
data during at least 2 cycles of bevacizumab-containing therapy
were available in 101 of these patients. Eleven patients were
excluded due to short treatment duration (0.07–1.08 months).
Reasons for early discontinuation were clinical progression
without radiological assessment and sufficient blood pressure
measurements (n¼5) or toxicity leading to early cessation of
therapy (venous thromboembolism, n¼2; myocardial ischaemia,
n¼2; bowel perforation, n¼1; proteinuria, n¼1). Two patients
had non-evaluable disease.
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sAt the time of inclusion, the following criteria were used as
contraindication for bevacizumab treatment: brain metastases,
high-dose NSAIDs, prior pulmonary embolism or recent venous
thromboembolic event, any arterial thromboembolic event,
or baseline Xgrade 2 proteinuria. Data cut-off was set at
24 November 2010, and by that time 91 (90%) patients had died.
The median follow-up time for patients alive (n¼10) was 63.5
months (range 20.6–73.6 months). This retrospective, single-centre
exploratory study was approved by an Institutional Review Board.
The dose of bevacizumab was 5mgkg
 1 every 2 weeks (n¼72)
or 7.5mgkg
 1 every 3 weeks (n¼29). None of the patients had
received prior antiangiogenic therapy. Sixty patients (59%)
received bevacizumab with 5-FU/LV/irinotecan (FOLFIRI) and
the rest of the patients received bevacizumab combined with
single-agent irinotecan or irinotecanþcapecitabine (n¼21),
oxaliplatin-based therapy (n¼12), or 5-FU-based therapy
(n¼7). One dihydropyrimidine dehydrogenase-deficient patient
received single-agent bevacizumab.
Seventy eight (77%) of the patients received further systemic
therapy after progression on bevacizumab-containing regimen. All
of the three most important chemotherapeutic agents for mCRC
(5-FU, oxaliplatin, and irinotecan) were used at some phase of the
treatment in 86 (85%) of the patients, in 88% of the hypertensive
and 82% of the normotensive patients (P¼0.41). Bevacizumab
beyond progression was given to 14 (14%) patients. Only
17 patients (17%) received cetuximab treatment after bevacizumab
failure.
Assessment of efficacy, side effects, and blood pressure
Patient demographics, adverse events, hospitalisations, and treat-
ment efficacy were available and collected from all patients.
Treatment response was evaluated according to RECIST criteria
by whole body spiral computerised tomography performed every
8–10 weeks.
Blood pressure was measured by a nurse in resting position
(after minimum 10min rest) at baseline and before each
bevacizumab infusion (starting at 14–21 days from treatment
initiation) in an outpatient department. If HTN emerged in a single
measurement, patients measured blood pressure 2–4 times weekly
at home. Blood pressure data was filed at baseline and every
3 months, thereafter until 2 years. Three monthly was chosen
because a new cycle is due at this time point in both 2 and 3 weekly
dosing. Early HTN was additionally recorded at 1 month; that is, at
3 or 4 weeks depending on the schedule.
Hypertension was defined according to the common toxicity
criteria for adverse events version 3.0 (CTCAE v3.0) as follows:
Grade 1, transient (o24h), asymptomatic, blood pressure rise by
20mmHg (diastolic) or to 4150/100mmHg, if previously normal;
Grade 2, recurrent, persistent, or symptomatic rise in diastolic
blood pressure 420mmHg or systolic blood pressure rise to
4150/100mmHg, if previously normal (monotherapy with anti-
hypertensive agents may be indicated); Grade 3, requiring more
than one drug therapy or more intensive therapy than previously.
Statistical analyses
The variables with non-normal distributions were compared with
the Mann–Whitney U-test, and the w
2-test was used for categorical
variables.
The association between HTN and OS and progression-free
survival (PFS) was described using the Kaplan–Meier survival
curves, and the log-rank test was used for group comparisons.
Overall survival was defined as the time from the date of initiation
of bevacizumab-containing therapy to the date of death from any
cause. Progression-free survival was defined as the time from the
date of initiation of the bevacizumab-containing therapy to the day
of documented disease progression or death due to any cause.
Patients without documented event were censored at last follow-
up, and two patients were censored at time of metastasectomy with
curative intent.
The landmark survival analysis (with the landmark set at
3 months after date of initiation of bevacizumab-containing therapy)
was performed. The landmark method was applied to avoid the bias
caused by the time-dependent definition of HTN. Overall survival
t i m ew a sd e f i n e da st h et i m ef r o mt h el a n d m a r kt i m et ot h ed a t eo f
death from any cause. For survival times, two patients were censored
at the time of operation with curative intent, and one patient was
excluded due to death before the landmark time point.
The univariate analyses were performed using the Cox propor-
tional hazards models with HTN status at the landmark time and
baseline characteristics (such as age, gender, primary tumour, line
of treatment, baseline WHO performance status, number of
metastatic sites) as independent variables. Then, the statistically
significant (Po0.05) prognostic variables given by the univariate
analyses were included as covariates together with HTN status in
the multivariate Cox model. The results are given as hazard ratios
(HR) with 95% confidence intervals (CI95%).
All statistical analyses were performed using a StatView
statistical package (Berkley, CA, USA), sigma-plot version 11
(Systat software corporation, Chicago, IL, USA), or SPSS version
18.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient population and efficacy of the treatment
In total, 101 patients, who initiated bevacizumab-containing
treatment for mCRC between April 2004 and December 2005,
were evaluated. Patient baseline demographics are shown in
Table 1.
The median duration of bevacizumab-containing therapy
was 8.6 months (range, 1.2–70.5). For patients who received
Table 1 Patient baseline demographics
All,
n¼101
(%)
No hyper-
tension,
n¼44
(44%)
Hypertension
grade 1–3,
n¼57 (56%) P-value
Median age, years
(range)
59.0 (35–79) 56.4 (35–76) 61.0 (43–79) 0.051
a
Gender 0.162
a
Male 54 (53) 27 (61) 27 (47)
Female 47 (47) 17 (39) 30 (53)
Primary site 0.517
a
Colon 56 (55) 26 (59) 30 (53)
Rectal 45 (45) 18 (41) 27 (47)
WHO performance
status
0.192
a
0 33 (33) 11 (25) 22 (39)
1 57 (56) 26 (59) 31 (54)
2 11 (11) 7 (16) 4 (7)
No. of metastatic sites 0.0020
a
1 33 (33) 7 (16) 26 (46)
2 17 (17) 9 (20) 8 (14)
X3 51 (50) 28 (64) 23 (40)
Line of treatment 0.567
a
First 33 (32) 12 (27) 21 (37)
Second 39 (39) 19 (43) 20 (35)
Third–seventh 29 (29) 13 (30) 16 (28)
Chemotherapy used 0.321
a
5-Fluorouracil based 7 (7) 5 (11) 2 (3)
Irinotecan based 81 (80) 35 (80) 46 (81)
Oxaliplatin based 12 (12) 4 (9) 8 (14)
No chemotherapy 1 (1) 0 (0) 1 (2)
aw
2-test.
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median duration of therapy was 12.0 months (range, 1.2–68)
compared with 7.5 (range, 1.3–70.5) and 6.6 months (range,
1.9–27) for those who received bevacizumab as second (n¼39) or
later; that is, third- to seventh-line (n¼29) therapy. At the time of
analysis (median follow-up 63.5 months), 100 (99%) of the patients
had progressed and 90 (89%) had died. There were no treatment-
related deaths.
The overall response rate (RR) was 50% and the disease control
rate 89%. Radiological complete response was achieved in six (6%)
patients. The median PFS was 8.8 months (CI95%: 8.0–9.6) and OS
18.9 months (CI95%: 15.1–22.7).
Effect of HTN on outcome
A total of 57 (56%) patients were diagnosed with Xgrade 1 HTN
(grade 1 (n¼26), grade 2 (n¼28), and grade 3 (n¼3)), whereas
the rest of the patients stayed normotensive (grade 0 (n¼44))
during bevacizumab treatment. Forty two (74%) of these Xgrade 1
HTN patients were normotensive at baseline and 15 (26%) were
normotensive with antihypertensives at baseline, but HTN
recurred during bevacizumab-containing treatment.
General guidelines for treatment of HTN were implemented and
antihypertensives were used in 30 patients. No group of
antihypertensives was favoured. Diuretics (n¼9), ACE/AT blockers
(n¼12), Ca-blockers (n¼6) and b-blockers (n¼12), and other
antihypertensives (n¼2) were used alone or in combination
(n¼9) making comparisons between drugs unmeaningful.
Medication was prescribed to six antihypertensives-naive patients
and intensified in one.
The frequency of the most important prognostic factors
(including treatment line, age, and WHO performance status)
were similar between hypertensive and normotensive patients.
However, the number of metastatic sites differed between the
groups (Table 1).
The median time to the onset of HTN was 1 month (range, 1–15
and within 6 months in 95%) as calculated from the start of
bevacizumab treatment. The median values of systolic and
diastolic blood pressure before and during bevacizumab-contain-
ing treatment are presented in Figure 1. There were no statistically
significant differences in the frequency of Xgrade 3 adverse
events, non-haematologic (21 vs 20, P¼0.90), and haematologic
(20 vs 14, P¼0.56), or arterial thromboembolic events (0 vs 2,
P¼0.10), between patients with (n¼57) or without HTN (n¼44).
Effect of HTN on patient outcomes (RR, PFS, and OS) are
presented in Table 2. Patients (n¼57) who developed Xgrade 1
HTN, had significantly longer OS than patients with no HTN
during the treatment (Po0.001); the median OS was 25.8 months
(CI95%: 19.2–32.4) for the patients with HTN vs 11.7 months
(CI95%: 7.2–16.1) for the normotensive (Figure 2). A similar
difference was also detected when PFS and OS of patients with
grade 0–1 HTN were compared with OS and PFS of patients with
grades 2–3 HTN.
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Figure 1 Systolic and diastolic blood pressure during bevacizumab
treatment in hypertensive (n¼57) and normotensive (n¼44) patients.
Median and 95% confidence interval.
Table 2 Treatment efficacy in the overall study population and in
subgroups divided by hypertension
All
(n¼101)
No hyper-
tension,
n¼44 (44%)
Hypertension
grade 1–3,
n¼57 (56%) P-value
Response rate* 0.025
a
CR/PR 50 20 30
SD 40 15 25
PD 11 9 2
Progression-free
survival (months)
8.8 5.3 10.5 0.008
b
Overall survival
(months)
18.9 11.7 25.8 o0.001
b
aw
2-test.
bLog-rank test. *According to Recist Criteria, CR¼complete response;
PR¼partial response; SD¼stable disease and PD¼progressive disease.
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Figure 2 Overall survival and progression-free survival by hypertension during bevacizumab-containing treatment.
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regardless of the treatment line as shown in Figure 3. Median OS of
first-line patients with treatment-related HTN was 28.8 (CI95%:
12.8–44.8) and 15.3 (CI95%: 14.0–16.6) months among patients
with no HTN (P¼0.291). In second-line bevacizumab treatment,
the OS was 30.3 (CI95%: 19.8–40.9) months among patients with
HTN and 10.9 (CI95%: 0.36–21.5; P¼0.028) among patients with
no HTN, whereas in third- to seventh-line treatment the OS
was 18.1 (CI95%: 12.1–24.0) vs 11.4 months (CI95%: 7.5–15.3;
P¼0.007), respectively.
A PFS benefit was also noted in favour of the hypertensive
group, 10.5 (CI95%: 9.0–12.0) vs 5.3 months (CI95%: 3.5–7.1;
P¼0.008; Figure 2). Furthermore, HTN was associated with
significantly more responses (30 vs 20%; P¼0.025). In patients
with Xgrade 1 HTN, only 4% had PD as best response, whereas
20% of the non-HTN patients had PD as best response.
Early HTN during bevacizumab therapy is predictive
for survival
We also performed univariate and multivariate analysis to find out
whether HTN within 3 months was an independent predictive
factor for treatment efficacy. We used the landmark model
in which each patient’s HTN status at 3 months (HTN, n¼48
and no HTN, n¼53) was determined. Survival was calculated from
that time point. One patient who had died before this landmark
time point was excluded from further analyses. Median OS for
patients with HTN at 3 months was 19.9 (CI95%: 15.7–24.1) and in
no HTN patients 12.3 months (CI95%:6 . 9–1 7 . 7 ;P¼0.020; Figure 4).
In univariate analysis, HTN within 3 months (HR 1.73,
P¼0.011) was a predictive factor for OS as well as WHO
performance status, line of treatment, number of metastatic sites,
and type of chemotherapy (Table 3). These significant factors were
added in a multivariate analysis, and bevacizumab treatment-
related HTN was an independent predictive factor (HR 0.53;
P¼0.007). Other predictive factors were line of treatment and
number of metastatic sites, whereas WHO performance status and
type of chemotherapy were no longer predictive (Table 3).
DISCUSSION
Bevacizumab-containing chemotherapy has been considered as a
standard treatment for mCRC since Hurwitz et al (2004) published
the pivotal study of the efficacy and tolerability of bevacizumab
in combination with irinotecan and 5-FU. However, not all
patients benefit from bevacizumab, but at present there are no
tools to predict the benefit of the addition of bevacizumab
to chemotherapy in mCRC. Different biomarkers such as B-raf and
K-ras mutation, microvessel density, VEGF, or VEGFR expression
have been widely studied, but so far no predictive factors have
been identified (Ince et al, 2005; Jubb et al, 2006).
Most common adverse events related to bevacizumab include
proteinuria, thromboembolic and wound healing complications,
gastrointestinal perforations and HTN. Data from pooled
randomised trials have shown that combination treatment with
bevacizumab and chemotherapy, compared with chemotherapy
alone, is associated with an increased risk of arterial thromboem-
bolism (Scappaticci et al, 2007). Although HTN has traditionally
been considered as a side effect of the treatment, it may represent a
measure of efficacy rather than toxicity. This assumption is
supported by our results as well as observations that mean systolic
and diastolic blood pressure of patients receiving VEGF signalling
pathway inhibitors increase with exposure to these drugs and
return to baseline after cessation of the treatment (Maitland et al,
2009). Studies by Maitland et al (2009) suggest that the wide
variability in blood pressure responses to VEGF pathway
inhibitors reflect pharmacodynamic variability. Additional data
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Figure 3 Effect of hypertension on overall survival by line of treatment.
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in these patients and to address whether there is a relationship
between HTN induced by various VEGF pathway inhibitors and
the incidence of cardiovascular side effects including reduced left
ventricular ejection fraction.
According to a recently published large meta-analysis (Ranpura
et al, 2010), the incidence of HTN in bevacizumab-treated cancer
patients was 23.6 with 7.9% being grade 3–4. Bevacizumab
treatment-related HTN is a very interesting subject at the moment.
We have earlier reported that HTN during bevacizumab treatment
in metastatic renal cell carcinoma (RCC) is associated with better
outcome. Similar data in metastatic RCC, breast cancer, and lung
cancer have also been published by others very recently (Schneider
et al, 2008; Dahlberg et al, 2010; Rini et al, 2010a). In patients with
mCRC, according to our knowledge, treatment-related HTN is a
subject very rarely evaluated even though bevacizumab is a routine
treatment in mCRC and in a wide use. Scartozzi et al (2009) have
conducted a retrospective study in a small patient population
(n¼39), in which eight patients developed HTN and were analysed
in detail. Our study identified 57 patients with HTN (56% of the
patients) and enabled us to do a considerably larger comparison
between patients with HTN and no HTN during bevacizumab-
containing treatment.
We have shown that early HTN, within 3 months of treatment
initiation, is predictive for OS. Similarly, Dahlberg et al (2010)
have shown that HTN within 1 month in bevacizumab therapy for
lung cancer is predictive for survival. Thus, it might be justifiable
to reconsider the continuation of bevacizumab at the first response
evaluation, and cessation in the absence of HTN may be wise if the
patient has poor tolerability, if economical restraints for the use of
the drug exist, or if alternative therapies are available, for example,
EGFR inhibitors.
It would have been interesting to monitor the blood pressure
more thoroughly also in this study, but the procedure used,
measuring blood pressure once before each infusion, was as
recommended in the Summary of Product Characteristics.
Prospective studies including ambulatory blood pressure monitor-
ing and pharmacodynamic analyses are also required in mCRC.
These could be able to disclose whether blood pressure elevation
predicts outcome and what is the source of pharmacodynamic
variability. As certain VEGF genotypes may protect against VEGF
signalling pathway inhibitor-induced HTN (Schneider et al, 2008),
such prospective studies may also find new strategies for
identifying patients at-risk for cardiovascular toxicities.
In conclusion, our results show that HTN predicted bevacizu-
mab treatment efficacy regardless of the analysed end point
(OS, PFS, or RR). It should be remembered that HTN is a known
risk factor for cardiovascular complications and therefore
effective treatment of bevacizumab-related HTN is recommended.
(Ranpura et al, 2010).
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